Latest Stocks: Boston Scientific Co. (BSX) Shares Sold by Suntrust Banks Inc.

Latest Stocks: Boston Scientific Co. (BSX) Shares Sold by Suntrust Banks Inc.

Suntrust Banks Inc. lowered its position in shares of Boston Scientific Co. (NYSE:BSX) by 26.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 47,013 shares of the medical equipment provider’s stock after selling 16,608 shares during the period. Suntrust Banks Inc.’s holdings in Boston Scientific were worth $1,169,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Checchi Capital Advisers LLC boosted its stake in Boston Scientific by 2.6% in the first quarter. Checchi Capital Advisers LLC now owns 13,553 shares of the medical equipment provider’s stock worth $337,000 after buying an additional 349 shares during the last quarter. HPM Partners LLC purchased a new stake in shares of Boston Scientific during the first quarter valued at $2,718,000. Capital Fund Management S.A. boosted its stake in shares of Boston Scientific by 533.5% in the first quarter. Capital Fund Management S.A. now owns 523,318 shares of the medical equipment provider’s stock valued at $13,015,000 after buying an additional 440,717 shares in the last quarter. DekaBank Deutsche Girozentrale boosted its stake in shares of Boston Scientific by 50.5% in the first quarter. DekaBank Deutsche Girozentrale now owns 317,348 shares of the medical equipment provider’s stock valued at $7,855,000 after buying an additional 106,533 shares in the last quarter. Finally, Diamond Hill Capital Management Inc. boosted its stake in shares of Boston Scientific by 0.3% in the first quarter. Diamond Hill Capital Management Inc. now owns 3,361,258 shares of the medical equipment provider’s stock valued at $83,594,000 after buying an additional 9,850 shares in the last quarter. 91.70% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Co. (NYSE BSX) opened at 27.51 on Tuesday. The stock has a 50 day moving average of $26.32 and a 200 day moving average of $24.17. Boston Scientific Co. has a 12 month low of $19.67 and a 12 month high of $27.78. The firm has a market capitalization of $37.67 billion, a PE ratio of 88.17 and a beta of 1.06.

Several analysts have recently commented on the stock. Needham & Company LLC reissued a “buy” rating and set a $29.00 price target on shares of Boston Scientific in a research note on Thursday, February 23rd. Zacks Investment Research lowered shares of Boston Scientific from a “hold” rating to a “sell” rating in a report on Wednesday, April 5th. Northland Securities restated a “positive” rating on shares of Boston Scientific in a report on Thursday, February 23rd. TheStreet lowered shares of Boston Scientific from a “b” rating to a “c+” rating in a report on Thursday, March 16th. Finally, Oppenheimer Holdings Inc. reiterated a “hold” rating on shares of Boston Scientific in a report on Thursday, February 23rd. Six research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $28.03. In other Boston Scientific news, SVP John Bradley Sorenson sold 2,950 shares of the business’s stock in a transaction dated Monday, April 10th. The stock was sold at an average price of $24.66, for a total value of $72,747.00. Following the completion of the transaction, the senior vice president now owns 20,980 shares of the company’s stock, valued at approximately $517,366.80. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Michael P. Phalen sold 79,045 shares of the business’s stock in a transaction dated Wednesday, March 29th. The stock was sold at an average price of $24.55, for a total value of $1,940,554.75. The disclosure for this sale can be found here. In the last three months, insiders sold 204,354 shares of company stock valued at $5,226,804. 1.31% of the stock is owned by insiders.

Receive News & Ratings for Boston Scientific Co. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Boston Scientific Co. and related companies with our FREE daily email newsletter.

Related posts

Leave a Comment